Fact checked byHeather Biele

Read more

November 30, 2022
1 min read
Save

Pancreatic cancer screening yields moderate benefit, ‘no harms’ for high-risk patients

Fact checked byHeather Biele
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHARLOTTE, N.C. — Pancreatic cancer screenings in high-risk individuals identified high-risk lesions in nearly 1% of patients and intermediate-risk pathology in more than 30%, according to data presented at the ACG Annual Scientific Meeting.

“Although pancreatic cancer screening has been increasingly studied in the last few years, there is a large variation in the yield, outcomes and harms of this screening in the literature,” Andy Silva-Santisteban, MD, a research fellow at the Center for Advanced Endoscopy at Beth Israel Deaconess Medical Center, told Healio. “To overcome these limitations, we proposed a large, multicenter prospective cohort study conducted at five academic medical institutions across the United States.”

Researcher quote

Silva-Santisteban and colleagues prospectively enrolled 252 high-risk patients (mean age, 59.9 years; 69% women) who underwent endoscopic ultrasound (n = 208) or magnetic resonance cholangiopancreatography (n = 44) for pancreatic cancer screening. Genetic susceptibility was the leading indication for screening.

According to results, low-risk pancreatic pathology was detected in 23.4% of patients, while intermediate-risk lesions were found in 31.7% of patients. High-risk lesions — which were identified as adenocarcinoma — were found in 0.8% of patients, which Silva-Santisteban noted was “at the lower end of the range that has been reported in the literature.”

In addition, new-onset prediabetes was noted in 18.2% of screened patients and new-onset diabetes in 1.7%.

The researchers reported no adverse events during screening, and that no patient underwent low-yield pancreatic cancer surgery.

“Patients should be carefully counseled regarding benefits and harms from pancreatic cancer screening,” Silva-Santisteban said. “When feasible, such screening should be performed within the confines of a research study, so data to inform future decisions may be collected.”

He added, “Other high-quality, large multicenter studies should be undertaken using standardized protocols to evaluate the yield of pancreatic cancer in at-risk patients, adverse effects of [endoscopic ultrasound] and MRI as methods of screening and other important outcomes such as identification of high-risk pancreatic lesions, new-onset diabetes and survival of affected patients.”